Molecular structure of Laninamivir
Laninamivir (CAS 203120-17-6)
Alternate Names:
5-(Acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-7-O-methyl-D-glycero-D-galacto-Non-2-enonic Acid; (4S,5R,6R)-5-Acetamido-4-guanidino-6- ((1R,2R)-2,3-dihydroxy-1-methoxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic Acid; R 125489
Application:
Laninamivir is a new potent neuraminidase (NA) inhibitor, which shows long-acting anti-influenza virus activity
CAS Number:
203120-17-6
Molecular Weight:
346.34
Molecular Formula:
C13H22N4O7
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Laninamivir is a new potent neuraminidase (NA) inhibitor, which shows long-acting anti-influenza virus activity. This chemical have a strong NA inhibitory activities against various influenza viruses, including those that are resistant to oseltamivir. The potency of Laninamivir (R-125489) as an influenza neuraminidase (NA) inhibitor is evident with IC50s of 0.90 nM, 1.83 nM, and 3.12 nM against avian H12N5 NA (N5), pH1N1 N1 NA (p09N1), and A/RI/5+/1957 H2N2 N2 (p57N2), respectively.
Laninamivir (CAS 203120-17-6) References
- Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. | Kubo, S., et al. 2010. Antimicrob Agents Chemother. 54: 1256-64. PMID: 20047917
- High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals. | Kubo, S., et al. 2012. J Infect Chemother. 18: 69-74. PMID: 21881920
- Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. | Vavricka, CJ., et al. 2011. PLoS Pathog. 7: e1002249. PMID: 22028647
- Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1. | Meeprasert, A., et al. 2012. J Mol Graph Model. 38: 148-54. PMID: 23079644
- Peramivir and laninamivir susceptibility of circulating influenza A and B viruses. | Leang, SK., et al. 2014. Influenza Other Respir Viruses. 8: 135-9. PMID: 24734292
- Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir. | Samson, M., et al. 2014. Antimicrob Agents Chemother. 58: 5220-8. PMID: 24957832
- Organocatalytic and scalable synthesis of the anti-influenza drugs zanamivir, laninamivir, and CS-8958. | Tian, J., et al. 2014. Angew Chem Int Ed Engl. 53: 13885-8. PMID: 25314609
- Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation. | McKimm-Breschkin, JL. and Barrett, S. 2015. Antiviral Res. 114: 62-6. PMID: 25499124
- Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection. | Panozzo, J., et al. 2015. Antiviral Res. 120: 66-71. PMID: 26022199
- Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan. | Azuma, T., et al. 2015. PLoS One. 10: e0131412. PMID: 26110817
- Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets. | Ann, J., et al. 2016. Influenza Other Respir Viruses. 10: 122-6. PMID: 26526406
- Drug-induced pneumonitis following the administration of laninamivir octanoate: The first two reported cases. | Ogawa, T., et al. 2019. J Infect Chemother. 25: 1043-1046. PMID: 31178281
- A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. | Moriguchi, T., et al. 2020. Int J Infect Dis. 94: 55-58. PMID: 32251791
- Laninamivir-Interferon Lambda 1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly than Laninamivir Alone. | Adams, SE., et al. 2020. Antimicrob Agents Chemother. 64: PMID: 32393488
- In Vitro Profiling of Laninamivir-Resistant Substitutions in N3 to N9 Avian Influenza Virus Neuraminidase Subtypes and Their Association with In Vivo Susceptibility. | Jeong, JH., et al. 2020. J Virol. 95: PMID: 33055248
Inhibitor of:
ADAM11, ADAM30, C4BPαZ, HN1, Influenza A NP, Influenza A pb1, Influenza A Virus Hemagglutinin, Influenza B, NDV HN, Neuramidase, from A. ureafaciens, Neuramidase, from V. cholerae, Neuraminidase, Neuraminidase, from C. perfringens, and SIAE.Activator of:
MANBAL, MD-2, Neuramidase, from V. cholerae, and Neuraminidase, from C. perfringens.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Laninamivir, 500 µg | sc-488700 | 500 µg | $411.00 | |||
Laninamivir, 5 mg | sc-488700A | 5 mg | $2710.00 | |||
Laninamivir, 50 mg | sc-488700B | 50 mg | $18212.00 | |||
Laninamivir, 100 mg | sc-488700C | 100 mg | $27417.00 | |||
Laninamivir, 250 mg | sc-488700D | 250 mg | $41101.00 | |||
Laninamivir, 1 g | sc-488700E | 1 g | $70752.00 |